Minimising the extent of diversion and injection of the pharmaceutical opioids used in opioid substitution treatment (OST) reduces harms to the individual (such as dependence, injection-related injuries and diseases, and overdose) and protects the integrity of the OST program.
This study will shed light on how policy gets formed by police, and what influences the policy formulation process.
Researchers, health professionals, consumer groups and advocates in the field have repeatedly called for widespread availability of naloxone for people who inject drugs and potential overdose witnesses, to reduce the incidence of fatal overdose.
Heroin use and associated harms can be reduced through effective treatment. Past research has shown that treatment for heroin dependence can be relatively cost-effective, but not whether heroin treatment overall is a good investment.
Heroin dependence is remarkably persistent, and in many cases it is a lifelong condition with a high mortality rate. Yet, the natural history of heroin dependence has rarely been studied.
The Drugs and New Technologies (DNeT) project aims to investigate drug marketplaces online and in other emerging technologies. It aims to assess and quantify the online availability of drugs, including both traditional and new psychoactive substances.
There has been a recent increase in the prescribing of pharmaceutical opioids to Chronic Non-Cancer Pain (CNCP) patients in Australia which has led to increasing professional and public concern about the use and harms that may be related to such use.
NIDIP was established in the recognition that there was a greater need for the regular dissemination of trends in the epidemiology of drug-related harms in Australia.
There are growing efforts by pharmaceutical companies to develop opioid formulations that are less prone to misuse (particularly injection), dependence and diversion to illicit markets.